Invectys

Executive Summary

Invectys is a French biotechnology company focused on developing novel RNA and gene therapy-based immunotherapies for oncology. Founded in 2010 and headquartered in Paris, the company aims to address high unmet medical needs by harnessing the immune system to target cancer antigens. Its platform leverages proprietary technologies to stimulate tumor-specific immune responses, potentially offering safer and more effective alternatives to conventional treatments. While still in preclinical or early clinical stages, Invectys has the potential to advance promising candidates into the clinic, particularly in indications with limited therapeutic options. The company's progress will depend on successful regulatory filings, clinical data generation, and securing partnerships or funding to support development.

Upcoming Catalysts (preview)

• Q2 2026IND/CTA Filing for Lead Program70% success
• Q4 2026Initial Phase I/II Clinical Data Readout50% success
• Q3 2026Strategic Partnership or Licensing Deal40% success